1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
T32 Training Program in Genetic and Neurobehavioral Mechanisms of Addiction is sponsored by National Institute on Drug Abuse (NIDA) - NIH. This training program focuses on predoctoral and postdoctoral trainees at the intersection of clinical psychology, clinical neuroscience, and behavioral genetics to understand the causes and consequences of substance use and addiction.
It emphasizes providing trainees with skills to analyze data from large-scale genetic and neuroimaging studies.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Predoctoral trainees (graduate students in the Department of Psychology) and postdoctoral trainees. Confirm the full requirements in the official notice before applying.
T32 Training Program in Genetic and Neurobehavioral Mechanisms of Addiction is funded by National Institute on Drug Abuse (NIDA) - NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) - NIH. HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 Clinical Trial Optional) is a grant from the National Institute on Drug Abuse (NIDA) at NIH that funds small business concerns to develop science-based technologies add…
Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed) is sponsored by National Institute on Drug Abuse (NIDA) - NIH. This SBIR program aims to leverage AI/ML tools to identify pharmacotherapeutic development candidates with lower toxicity and higher efficacy to prevent or treat Substance Use Disorders (SUDs).
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article